Taking into consideration the aforesaid facts that long-term l-dopa treatment is a risk factor for developing PD dementia and that l-dopa-induced dyskinesia correlate with cognitive decline, it is possible that blocking AT1R may decrease the risk of cognitive decline. The gene discussed is AGTR1; the disease is Dyskinesia.